Biowave Corp.
This article was originally published in Start Up
Executive Summary
Biowave hopes to ease the suffering of those with chronic pain with non-invasive and minimally invasive neuromodulation technology. Its devices--one designed for in-hospital use, one for home use--deliver a penetrating focused electrical field into deep tissue to block pain at its source.
You may also be interested in...
Neuromodulation: Devices's Stimulating Growth Market
According to "Opportunities in Global Medical Devices and Diagnostics," a report recently published by Health Research International that forecasts growth rates in seven major clinical segments and 20 major technology segments, neuromodulation will experience the highest growth rate of all the top-tier segments over the next five years, in excess of 18%. The neuromodulation segment posted sales of approximately $1.7 billion in 2005 and will be worth almost $4 billion in 2010, HRI predicts.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.